Trodelvy Injection (sacituzumab govitecan) 180 mg Side Effects & Price
Trodelvy (sacituzumab govitecan) is a prescription medication used to treat metastatic triple-negative breast cancer (TNBC) and metastatic urothelial cancer. It is given as an intravenous infusion (injection into a vein) by a healthcare professional.
The recommended dosage of Trodelvy is 10 mg/kg of body weight administered on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity. The dosage may be adjusted based on the patient's response to the medication and any side effects.
Trodelvy works by targeting a protein called Trop-2, which is overexpressed in certain types of cancer cells, including TNBC and urothelial cancer. By attaching to Trop-2, Trodelvy delivers a chemotherapy drug directly to the cancer cells, which can help to destroy the cancer cells and slow down the growth of the tumor.
Common side effects of Trodelvy include nausea, diarrhea, fatigue, hair loss, decreased appetite, and low white blood cell count. Trodelvy can also cause serious side effects, such as severe neutropenia (low white blood cell count), infections, and infusion-related reactions. Patients should inform their healthcare provider immediately if they experience any of these symptoms or side effects.
It is important to discuss any potential risks and benefits of Trodelvy with your healthcare provider before starting treatment. You should also inform your healthcare provider if you have a history of infections or other medical conditions, as well as any medications you are currently taking.
Comments
Post a Comment